SR 146131

Known as: SR-146131, SR146131 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2002
01219992002

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
Abstract Rationale. Converging evidence has demonstrated that cholecystokinin (CCK) inhibits mesolimbic brain dopamine (DA… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2000
2000
1-[2-(4-(2-Chlorophenyl)thiazol-2-yl) aminocarbonyl indoyl] acetic acid (SR 27897) is an effective CCK(1) receptor antagonist… (More)
Is this relevant?
2000
2000
The effect of ¿2-[4-(4-chloro-2, 5-dimethoxy-phenyl)-5-[2-cyclohexyl-ethyl)-thiazol-2-ylcarbamoy l]-5, 7-dimethyl-indol-1-yl… (More)
Is this relevant?
2000
2000
We hypothesized that charge-charge interactions may be important for the binding of the human cholecystokinin type 1 (CCK(1… (More)
Is this relevant?
1999
1999
SR146131 inhibited the binding of [125I]-Bolton Hunter (BH)-sulfated cholecystokinin octapeptide (CCK-8S) for the human… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 6
Is this relevant?
1999
1999
SR146131 is a potent and selective agonist at cholecystokinin subtype 1 (CCK1) receptors in vitro. The present study evaluates… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?